<DOC>
	<DOCNO>NCT00722371</DOCNO>
	<brief_summary>A study evaluate efficacy safety sitagliptin pioglitazone co-administration comparison sitagliptin pioglitazone monotherapy patient type 2 diabetes .</brief_summary>
	<brief_title>MK0431 Pioglitazone Co-Administration Factorial Study Patients With Type 2 Diabetes Mellitus ( 0431-102 AM2 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient highly unlikely conceive Patient meet one 3 category naïve antihyperglycemic agent ( AHA ) therapy , nonnaïve base upon patient 's current diet , medical regimen screen A1c patient currently AHA screen A1c &gt; =7.5 % = &lt; 11.0 % patient currently either metformin pr sulfonylurea monotherapy screen A1c &gt; =7.0 % = &lt; 9.0 % Exclusion Criteria Patient history type 1 diabetes mellitus history ketoacidosis C=peptide value = &lt; 0.8 ng/mL Patient previously treat insulin , thiazolidinedione ( TZD ) ( rosiglitazone pioglitazone ) , Dipeptidyl peptidase4 ( DPP4 ) inhibitor ( sitagliptin , vildagliptin , alogliptin ) , exenatide previously clinical study DPP4 inhibitor incretin mimetic Patient weight loss program maintenance phase start weight loss medication ( e.g . orlistat sibutramine ) within prior 8 week Patient undergone surgery within prior 30 day major surgery plan study Patient medical history active liver disease include chronic active hepatitis B C symptomatic gallbladder disease include primary biliary cirrhosis Patient receive treatment investigational product within 12 week prior Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>